Stock Track | Senseonics (SENS) Soars 5.44% Pre-Market on Eversense 365 Success and Growth Plans

Stock Track

Jan 06, 2025

Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.

In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.

Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128142543"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128142543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128142543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-06 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128142543","market":"hk","top_or_hot":-1,"title":"Stock Track | Senseonics (SENS) Soars 5.44% Pre-Market on Eversense 365 Success and Growth Plans","media":"Stock Track","content":"<p>Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.</p>\n\n<p>In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.</p>\n\n<p>Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Senseonics (SENS) Soars 5.44% Pre-Market on Eversense 365 Success and Growth Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Senseonics (SENS) Soars 5.44% Pre-Market on Eversense 365 Success and Growth Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-06 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.</p>\n\n<p>In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.</p>\n\n<p>Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SENS","symbol_name":"Senseonics Holdings,Inc.","start_time":0,"source_url":"","article_id":"1128142543","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128142543","pubTimestamp":1736176469,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Senseonics Holdings, Inc. , a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"translate_title":"股票跟踪Senseonics(SENS)因Eversense 365成功和增长计划而盘前飙升5.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1},"content_text":"Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.\nIn the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.\nBuilding on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}